Doer Biologics Announces Completion of First Cohort Dosing in Phase I Clinical Trial of DR10624 in China
Doer Biologics
Biological Drug Developer
Hangzhou, China, October 13, 2023 – Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), a clinical-stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancer, today announced itsThe World's First Innovative Drug DR10624 with Three Targets and Multi-SpecificityCompleted the dosing of the first cohort (a total of 12 subjects) in the Phase I single ascending dose (SAD) clinical trial for weight management indications in overweight or obese populations in China.
The Phase I Single Ascending Dose (SAD) study of DR10624 in China is a randomized, placebo-controlled, double-blind study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single subcutaneous doses of DR10624 with dose escalation. Currently, DR10624 is undergoing SAD studies in both New Zealand and China, while Multiple Ascending Dose (MAD) clinical trials are also being conducted in New Zealand. The first subject in the MAD study was dosed in July 2023.
Dr. Huangyanshan
Founder & CEO of Doer Biologics
Dr. Huang Yanshan, founder and CEO of Doer Biologics, stated: "DR10624 is a globally first-in-class (FIC) tri-specific biologic drug designed, modified, and developed using Doer Biologics' proprietary MultipleBody® platform technology. It specifically activates glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and fibroblast growth factor 21 receptor (FGF21R). In preclinical experiments, DR10624 demonstrated promising efficacy in weight loss, metabolic improvement, and liver function restoration."
Dr. Yongliang Fang
Chief Operating Officer of Doer Biologics
Dr. Yongliang Fang, Chief Operating Officer of Doer Biologics, commented, "We are encouraged by the progress of the SAD study for DR10624 currently underway in China. DR10624 is concurrently undergoing SAD and MAD trials in New Zealand, where it has already demonstrated favorable safety, tolerability, and preliminary efficacy signals. The completion of dosing for the first cohort of subjects in the SAD study in China marks another significant advancement in the clinical development of DR10624 in China."
More information about the Phase I SAD clinical trial of DR10624 in China can be found on the Drug Clinical Trial Registration and Information Disclosure Platform (Registration No.: CTR20232684).
About Doer Biologics
Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") is a clinical-stage biopharmaceutical company focused on the discovery and development of multi-specific biotherapeutics based on multi-domain structures to address unmet medical needs in the fields of metabolic diseases and cancer.
Doer Biologics has developed a variety of proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody.
For more information about Doer Biologics, please visit www.doerbio.com.